A randomized, controlled study of once-daily LY2605541, a novel long-acting basal insulin, versus insulin glargine in basal insulin-treated patients with type 2 diabetes
Richard M Bergenstal, Julio Rosenstock, Richard F Arakaki, Melvin J Prince, Yongming Qu, Vikram P Sinha, Daniel C Howey, Scott J Jacober, Richard M Bergenstal, Julio Rosenstock, Richard F Arakaki, Melvin J Prince, Yongming Qu, Vikram P Sinha, Daniel C Howey, Scott J Jacober
Abstract
Objective: To evaluate whether LY2605541 results in lower fasting blood glucose (FBG) versus insulin glargine (GL).
Research design and methods: This 12-week, randomized, open-label, Phase 2 study enrolled patients with type 2 diabetes (hemoglobin A(1c) [A1C] ≤ 10.5%), taking metformin and/or sulfonylurea with GL or NPH insulin once daily. Patients converted to morning insulin administration during lead-in were randomized 2:1 from GL (n = 248) or NPH insulin (n = 39) to LY2605541 (n = 195) or GL (n = 95) once daily in the morning.
Results: At 12 weeks, FBG (mean ± SE) was similar with LY2605541 and GL (118.2 ± 2.0 mg/dL [6.6 ± 0.1 mmol/L] vs. 116.9 ± 2.7 mg/dL [6.5 ± 0.2 mmol/L], P = 0.433) as was A1C (7.0 ± 0.1 vs. 7.2 ± 0.1%, P = 0.279). Intraday blood glucose variability was reduced with LY2605541 (34.4 vs. 39.1 mg/dL [1.9 vs. 2.2 mmol/L], P = 0.031). LY2605541 patients had weight loss (-0.6 ± 0.2 kg, P = 0.007), whereas GL patients gained weight (0.3 ± 0.2 kg, P = 0.662; treatment difference: -0.8 kg, P = 0.001). The incidence and rate of both total hypoglycemia and nocturnal hypoglycemia were comparable between LY2605541 and GL, although, LY2605541 had a 48% reduction in nocturnal hypoglycemia after adjusting for baseline hypoglycemia (P = 0.021). Adverse events were similar across treatments. Alanine aminotransferase and aspartate aminotransferase remained within normal range but were significantly higher with LY2605541 (P ≤ 0.001).
Conclusions: In patients with type 2 diabetes, LY2605541 and GL had comparable glucose control and total hypoglycemia rates, but LY2605541 showed reduced intraday variability, lower nocturnal hypoglycemia, and weight loss relative to GL.
Trial registration: ClinicalTrials.gov NCT01027871.
Figures
References
- Riddle MC, Rosenstock J, Gerich J, Insulin Glargine 4002 Study Investigators The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003;26:3080–3086
- Buse JB, Wolffenbuttel BH, Herman WH, et al. DURAbility of basal versus lispro mix 75/25 insulin efficacy (DURABLE) trial 24-week results: safety and efficacy of insulin lispro mix 75/25 versus insulin glargine added to oral antihyperglycemic drugs in patients with type 2 diabetes. Diabetes Care 2009;32:1007–1013
- Nathan DM, Buse JB, Davidson MB, et al. American Diabetes Association. European Association for Study of Diabetes Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193–203
- Swinnen SG, Hoekstra JB, DeVries JH. Insulin therapy for type 2 diabetes. Diabetes Care 2009;32(Suppl. 2):S253–S259
- Bazzano LA, Lee LJ, Shi L, Reynolds K, Jackson JA, Fonseca V. Safety and efficacy of glargine compared with NPH insulin for the treatment of Type 2 diabetes: a meta-analysis of randomized controlled trials. Diabet Med 2008;25:924–932
- World Medical Association Declaration of Helsinki World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 2000;284:3043–3045
- Yki-Järvinen H, Kauppinen-Mäkelin R, Tiikkainen M, et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia 2006;49:442–451
- Hansen RJ, Cutler GB Jr, Vick A, et al. Leveraging hydrodynamic size to develop a novel basal insulin (Abstract). Scientific Sessions of the American Diabetes Association; 8–11 June 2012; Philadelphia, PA, Poster # 896-P.
- Sinha VP, Howey DC, Soon D, et al. Single-dose pharmacokinetics (PK) and glucodynamics (GD) of the novel long-acting basal insulin LY2605541 in healthy subjects (Abstract). Scientific Sessions of the American Diabetes Association; 8–11 June 2012; Philadelphia, PA, Poster # 106-P.
- Heise T, Howey DC, Sinha VP, Choi SL, Mace KF. Steady-state pharmacokinetics (PK) and glucodynamics (GD) of the novel, long acting basal insulin LY2605541 dosed once-daily (QD) in patients with type 2 diabetes mellitus (T2DM) (Abstract). Scientific Sessions of the American Diabetes Association; 8–11 June 2012; Philadelphia, PA, Poster # 1000-P.
- Lantus (insulin glargine) prescribing information [Internet], 2007. Bridgewater, NJ, sanofi-aventis US. Available from Accessed 20 February 2012
- Levemir (insulin detemir) prescribing information [Internet], 2011. Princeton, NJ, Novo Nordisk. Available from Accessed 20 February 2012
- Mäkimattila S, Nikkilä K, Yki-Järvinen H. Causes of weight gain during insulin therapy with and without metformin in patients with Type II diabetes mellitus. Diabetologia 1999;42:406–412
- Bretzel RG, Nuber U, Landgraf W, Owens DR, Bradley C, Linn T. Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial. Lancet 2008;371:1073–1084
- Holman RR, Farmer AJ, Davies MJ, et al. 4-T Study Group Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med 2009;361:1736–1747
- Kudlacek S, Schernthaner G. The effect of insulin treatment on HbA1c, body weight and lipids in type 2 diabetic patients with secondary-failure to sulfonylureas. A five year follow-up study. Horm Metab Res 1992;24:478–483
- Rosenstock J, Bergenstal RM, Blevins T, et al. Better glycemic control and weight loss with the novel long-acting basal insulin LY2605541 compared with insulin glargine in patients with type 1 diabetes (Abstract). Scientific Sessions of the American Diabetes Association; 8–11 June 2012; Philadelphia, PA, Poster # 1026-P.
- Moore MC, Smith MS, Mace KF, et al. Novel PEGylated basal insulin LY2605541 has a preferential hepatic effect on glucose metabolism (Abstract). Scientific Sessions of the American Diabetes Association; 8–11 June 2012; Philadelphia, PA, Poster # 1609-P.
- Au JS, Navarro VJ, Rossi S. Review article: Drug-induced liver injury—its pathophysiology and evolving diagnostic tools. Aliment Pharmacol Ther 2011;34:11–20
- Navarro VJ, Senior JR. Drug-related hepatotoxicity. N Engl J Med 2006;354:731–739
Source: PubMed